表紙
市場調查報告書

糖尿病神經病變:開發中產品分析

Diabetic Neuropathy - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 192558
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
糖尿病神經病變:開發中產品分析 Diabetic Neuropathy - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 135 Pages
簡介

糖尿病神經病變是糖尿病最常見的併發症,是感知疼痛的神經受損,症狀有疼,發麻,灼熱感,疼痛等症狀。致病因子有肥胖、高血壓、高脂質·高血糖、抽煙。可以藥物治療和改善飲食習慣來控制。

本報告提供糖尿病神經病變的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

  • 調查範圍

糖尿病神經病變概要

治療藥的開發

  • 開發中產品:概要
  • 各企業的開發平台
  • 大學/研究機關開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Achelios Therapeutics Inc
  • Angelini Group
  • Apollo Endosurgery Inc
  • Araim Pharmaceuticals Inc
  • Celgene Corp
  • Commence Bio Inc
  • Grunenthal GmbH
  • Kineta Inc
  • KPI Therapeutics Inc
  • Medifron DBT Co Ltd
  • Neuralstem Inc
  • NovaLead Pharma Pvt Ltd
  • Omeros Corp
  • Reata Pharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • ViroMed Co Ltd

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12234IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2020, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

"Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics."

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 12, 8, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Diabetic Neuropathy - Overview
  • Diabetic Neuropathy - Therapeutics Development
  • Diabetic Neuropathy - Therapeutics Assessment
  • Diabetic Neuropathy - Companies Involved in Therapeutics Development
  • Diabetic Neuropathy - Drug Profiles
  • Diabetic Neuropathy - Dormant Projects
  • Diabetic Neuropathy - Discontinued Products
  • Diabetic Neuropathy - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Diabetic Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2020
  • Diabetic Neuropathy - Pipeline by Angelini Group, H1 2020
  • Diabetic Neuropathy - Pipeline by Applied Therapeutics Inc, H1 2020
  • Diabetic Neuropathy - Pipeline by Arena Pharmaceuticals Inc, H1 2020
  • Diabetic Neuropathy - Dormant Projects, H1 2020
  • Diabetic Neuropathy - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Diabetic Neuropathy - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Diabetic Neuropathy - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Diabetic Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020